文献速递糖尿病

LinX持续葡萄糖监测系统在成人糖尿病患者中的准确性与安全性:前瞻性多中心开放标签临床性能研究

Accuracy and Safety of the LinX Continuous Glucose Monitoring System in Adults With Diabetes: A Prospective Multicentre Open‐Label Clinical Performance Study
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-11-04

本研究为前瞻性多中心开放标签临床性能研究,纳入87名佩戴两个LinX传感器的成人糖尿病患者,以Biosen分析仪测糖为参考。总体MARD为8.66%(95%CI:8.27%–9.05%),15天传感器存活率96.0%,无严重不良事件。LinX CGM系统在15天佩戴期内显示出良好的分析准确性和短期安全性。

要点

  • 总体MARD为8.66%(95%CI:8.27%–9.05%)
  • 3.9–10.0 mmol/L范围内87.2%读数在±15%以内
  • 15天传感器存活率96.0%,无严重不良事件

核心结论

  • LinX CGM系统在成人糖尿病患者15天佩戴期内表现出良好的分析准确性和短期安全性。

研究设计与样本

  • 前瞻性、多中心、开放标签临床性能研究,纳入87名佩戴两个LinX传感器的成人糖尿病患者。
  • 参考葡萄糖采用Biosen分析仪测量。
  • 主要终点为读数落在参考值±15%/±40%内的比例及平均绝对相对差(MARD)。

主要发现

  • 总体MARD为8.66%(95%CI:8.27%–9.05%)。
  • 葡萄糖浓度3.9–10.0 mmol/L(70–180 mg/dL)范围内,87.2%读数在±15%以内。
  • 葡萄糖浓度≥10.0 mmol/L(≥180 mg/dL)范围内,90.2%读数在±15%以内。
  • ±40%范围内,上述两个浓度区间的符合率分别为99.8%和100.0%。
  • 15天传感器存活率为96.0%,未发生严重不良事件。

临床怎么用

  • LinX CGM系统可用于成人糖尿病患者的15天连续葡萄糖监测,准确性满足临床需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Background Accurate continuous glucose monitoring (CGM) is essential for diabetes management. This study evaluated the accuracy and safety of the LinX CGM system over 15 days in adults with diabetes. Methods In this prospective, multicentre, open-label clinical performance study, 87 adults who wore two LinX sensors were enrolled. Reference glucose was measured using a Biosen analyser. Primary endpoints were the proportions of readings within ±15%/±40% of reference values and mean absolute relative difference (MARD). Results Overall MARD was 8.66% (95% CI: 8.27%–9.05%). For glucose concentrations in the range of 3.9–10.0 mmol/L (70–180 mg/dL), 87.2% of readings were within ±15%; for concentrations ≥ 10.0 mmol/L (≥ 180 mg/dL), 90.2% were within ±15%. Within ±40%, agreement rates were 99.8% and 100.0%, respectively. Sensor survival at 15 days was 96.0%. No serious adverse events occurred. Conclusion The LinX CGM system demonstrated good analytical accuracy and favourable short-term safety over a 15-day wear period in adults with diabetes. Trial Registration: Chinese Clinical Trial Registry: ChiCTR2200064004

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:Accuracy and Safety of the LinX Continuous Glucose Monitoring System in Adults With Diabetes: A Prospective Multicentre Open‐Label Clinical Performance Study

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。